Clinical Trial Update: A Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 Inhibitors [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating sacituzumab govitecan in combination with endocrine therapy for HR-positive, HER2-negative metastatic breast cancer that progressed o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Sacituzumab Govitecan (sacituzumab govitecan)

Snippet

Sponsor: Hunan Cancer Hospital | Conditions: Stage IV (Metastatic) Breast Cancer | Phase 1 | Status: NOT_YET_RECRUITING